|
Trump's Drug Pricing Executive Order Harmful to Patients - Will Hinder Development of New Drugs
Fox News | Sally C. Pipes
July 24, 2020
President Trump issued four executive orders Friday that he said will lower drug prices — but in reality, three of the orders will cause far more harm than good and represent electioneering at its worst. The three harmful executive orders allow the importation of drugs from Canada, reduce the price of insulin, and introduce an International Pricing Index for prescription drugs.
|
|
President Trump's Big Government Instincts Threaten Drug Innovation and Availability
Forbes | Wayne Winegarden
July 24, 2020
President Reagan famously said, “the nine most terrifying words in the English language are: I’m from the Government and I’m here to help”. It is time for President Trump to learn this wisdom. Along with Speaker Pelosi, Senator Sanders, and Representative Ocasio-Cortez, President Trump seems to believe that giving the government the authority to impose price controls on medicines will help patients. And, following the signing ceremony on Friday, he is now officially trying to make government price controls a reality. |
|
COVID-19's Long Term Effects Raise the Stake of the Game
Human Events | Henry I. Miller, M.S., M.D.
July 23, 2020
Despite the surge of new cases of COVID-19, increases in the percentage of positive tests, and scores of ICUs at or near capacity, some commentators are still saying things like, “The so-called surge in cases is more fake news pushed by media cheerleaders eager to destroy the U.S. economy and culture if it makes Trump a one-term president,” and “in fact, our pandemic nightmare might well be coming to an end.” They and others emphasize that the daily number of Covid-19 deaths has been trending down since April (due to better medical management and the decreasing age of those infected, who have better outcomes than older persons). That is, of course, good news, but it is far from the whole story.
|
|
It's Time to Bring Our Economy Back to Life. Paying Workers to Stay Home Won't Help
Fox Business | Sally C. Pipes
July 25, 2020
The federal government's emergency unemployment benefits are set to expire this week. Set at $600 a week by the CARES Act -- the economic rescue package Congress passed back in March -- the emergency benefits were intended to supplement state unemployment insurance and offset the economic carnage caused by the coronavirus lockdowns.
|
|
Dr. Henry Miller on Next Round with PRI: What Scientists are Learning About COVID-19
Next Round with PRI
July 20, 2020
PRI senior fellow in health care studies Dr. Henry Miller joins “Next Round with PRI” to give an update on what scientists are learning about COVID-19 and the progress in finding a vaccine. He also weighs in on whether schools should be reopening this fall, gives his thoughts on what the Trump administration is doing good and bad in fighting the pandemic, and offers advices on how we can reduce our chances of getting the coronavirus. |
|
Sally Pipes and Lars Larson Examine Trump Executive Orders on Drug Pricing
The Lars Larson Show
July 14, 2020
Sally C. Pipes joins the Lars Larson Show to question the Trump administration’s latest action on drug pricing. President Trump plans to sign an executive order on Friday, July 24 that puts limits on drug pricing in the United States. Pipes explains that 90 percent of drugs are generic and already save most Americans a great deal of money. But the pending executive order ties the average reference drug price to those in other countries – Canada, UK, Germany, France, Australia. Pipes also explains the enormous costs of producing pharmaceutical drugs and what’s at stake for the cost of prescription drugs in the United States and other nations. |
|
|
Watch the Latest "Escape the Drug Pricing Maze Video"
The Affordability Problem
The Professor and Pete go to the movies to learn why there is a drug affordability problem. After watching a scary thriller about list prices and net prices, an adventure on the prescription escalator, and a movie on biosimilars, they learn that a) specific patient populations are impacted by the drug affordability problem; and b) these issues can be fixed with targeted reforms to achieve innovation and affordability.
|
|
|
|
